Mednet Logo
SpecialtiesAllergy & Immunology
Allergy & Immunology

Allergy & Immunology

Expert discussions on allergic conditions, immunodeficiencies, drug hypersensitivity, and immunotherapy approaches.

Recent Discussions

How do you manage atopic dermatitis in patients who have failed dupilumab?

2
2 Answers

Mednet Member
Mednet Member
Dermatology · University of California San Diego

The therapeutic landscape for atopic dermatitis is being updated every year, meaning that this question will have different answers in the next few years. In fact, new guidelines are being updated more frequently to capture new drug approvals. As always, medication selection should weigh risks and b...

Can venom immunotherapy cause ocular complications?

1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Johns Hopkins University School of Medicine

I know of no reported cases of ocular complications caused by VIT.This question has come to me before, after it was raised (by false association) in an AI search of VIT. It was traced to reported cases of intra-ocular stings in which the venom or an implanted stinger caused ocular complications (i.e...

Can a patient with mastocytosis be prescribed SCIT?

3 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Uniformed Services University

Yes, patients with systemic mastocytosis (SM) can be prescribed aeroallergen subcutaneous immunotherapy (SCIT) with caution in a practice that has the experience and resources needed to treat severe anaphylaxis. SM patients are at risk of severe anaphylaxis reactions to SCIT during buildup and maint...

How do you reassure families that no allergy testing is needed for urticaria?

1
2 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Asthma Allergy And Immunology Center

I explain to them that it is an immunologic phenomenon (inside job) and not allergic (outside job).

With emerging therapies, what is your general treatment ladder for chronic spontaneous urticaria (CSU)?

1
2 Answers

Mednet Member
Mednet Member
Dermatology · Harvard Medical School/Brigham and Women’s Hospital

Antihistamines remain the first-line therapy for chronic spontaneous urticaria (CSU), and doses should be optimized before turning to other therapies. If patients fail a trial of adequately dosed first- and second-generation antihistamines, montelukast is a reasonable adjunct. For patients with high...

Does receiving IVIG confound the result of SPEP and/or UPEP?

4
2 Answers

Mednet Member
Mednet Member
Hematology · John Theurer Cancer Center Hackensack Univ Med Center

IVIG being a product of polyclonal immunoglobulins may ‘produce’ a monoclonal spike if the AUC is falsely calculated by the reader. IFE usually shows polyclonal banding but every now and then a monoclonal band is picked up. Being an IgG molecule with a 21 day halflife; and with the assumption that i...

Does switching arms enhance the efficacy of subcutaneous allergen immunotherapy?

1
1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Washington University School of Medicine

I wish we knew. Many of us switch arms with immunotherapy doses routinely to try to minimize local reactions and "spread out allergen evenly," so to speak. It is the latter concept that is relevant to the question. I do not know of any data as it pertains to allergen immunotherapy. However, there is...

Do you use skin prick testing wheal size/grade or serum IgE levels when deciding what dose of allergen immunotherapy to start a patient on?

3
1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Washington University School of Medicine

Generally, regardless of the degree of sensitization, I start my patients' immunotherapy with a 1:1000 dilution and build up to 1:1 over several months. However, I may consider the degree of sensitization when writing the extract prescription. I typically dose in the lower range for allergens with m...

How long do you apply patch testing before interpreting the results?

1 Answers

Mednet Member
Mednet Member
Dermatology · University of Pennsylvania

In most instances, patches are removed after 48 hours (2 days). This timeframe is specifically chosen to allow sufficient time for the allergen to penetrate the stratum corneum and trigger a T-cell-mediated response, while simultaneously reducing the potential for significant skin irritation that ca...

What data exist regarding treatment for facial erythema from dupilumab in children <5 years of age?

2 Answers

Mednet Member
Mednet Member
Allergy & Immunology · University of Southern California

In AD patients &gt;6 years, the incidence of facial erythema for dupilumab was 1% vs placebo 0.7% (Paller et al., PMID 41163262). The placebo-controlled LIBERTY AD PRESCHOOL trial (Paller et al., PMID 36116481) and the subsequent open-label trial up to 2 years (Paller et al., PMID 41926052) for 6-month...